Mallinckrodt
-
Report: Prosecutors use Controlled Substances Act to investigate opioid makers, distributors
The Wall Street Journal reported that at least six companies’ disclosures that they had received subpoenas were related to the investigation, and subpoenas for additional companies are expected in the coming months.
-
Mallinckrodt stock tanks following report that it has hired restructuring advisers
Shares of the company fell 40 percent Thursday following a story late Wednesday afternoon by Bloomberg, which reported that a bankruptcy filing was a potential option.
-
Streamline the Process for Consent Collection and Management
Join us on April 16th and hear executives from DocuSign and Velatura discuss how their partnership modernizes and facilitates the efficient and secure completion of the patient consent form.
-
Humana sues drugmaker Mallinckrodt over alleged price gouging
Humana alleges that Mallinckrodt illegally jacked up the price of the injected drug Acthar, causing the insurance company to pay several times more for the drug – which the FDA approved in 1952 – than it otherwise would have.
-
Study highlights role of doctor conflicts of interest in Medicare spending on Mallinckrodt drug Acthar
Study published in JAMA indicates nearly 90 percent of doctors prescribing HP Acthar Gel took payments from drug’s manufacturer.
-
Morning Read: Mallinckrodt gets the Citron treatment (and what that means)
Also, Astellas and GE Healthcare make big buys, interesting insight on ResearchKit and AZ’s lupus treatment gets a boost.